NCT02213107 2024-11-13
Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.
University of Rochester
Phase 2 Completed
University of Rochester
Endeavor Health
CHU de Quebec-Universite Laval
University of Illinois at Chicago
University of Washington
Dana-Farber Cancer Institute
Kaunas University of Medicine
Canadian Urology Research Consortium
Dana-Farber Cancer Institute
Bay State Clinical Trials, Inc.
University of California, San Francisco
Roswell Park Cancer Institute
Sunnybrook Health Sciences Centre